Clinical Practice Guidelines in nephrology—for worse or for better

Paving the COWpath: Learning and visualizing clinical pathways from electronic health record data

OBJECTIVE

Clinical pathways translate best available evidence into practice, indicating the most widely applicable order of treatment interventions for particular treatment goals. We propose a practice-based clinical pathway development process and a data-driven methodology for extracting common clinical pathways from electronic health record (EHR) data that is patient-centered, consistent with clinical workflow, and facilitates evidence-based care.

MATERIALS AND METHODS

Visit data of 1,576 chronic kidney disease (CKD) patients who developed acute kidney injury (AKI) from 2009 to 2013 are extracted from the EHR. We model each patient's multi-dimensional clinical records into one-dimensional sequences using novel constructs designed to capture information on each visit's purpose, procedures, medications and diagnoses. Analysis and clustering on visit sequences identify distinct types of patient subgroups. Characterizing visit sequences as Markov chains, significant transitions are extracted and visualized into clinical pathways across subgroups.

RESULTS

We identified 31 patient subgroups whose extracted clinical pathways provide insights on how patients' conditions and medication prescriptions may progress over time. We identify pathways that show typical disease progression, practices that are consistent with guidelines, and sustainable improvements in patients' health conditions. Visualization of pathways depicts the likelihood and direction of disease progression under varied contexts.

DISCUSSION AND CONCLUSIONS

Accuracy of EHR data and diversity in patients' conditions and practice patterns are critical challenges in learning insightful practice-based clinical pathways. Learning and visualizing clinical pathways from actual practice data captured in the EHR may facilitate efficient practice review by healthcare providers and support patient engagement in shared decision making.

Clinical practice guidelines on wait-listing for kidney transplantation: consistent and equitable?

BACKGROUND

Apparent variability in wait-listing criteria globally has raised concern about inequitable access to kidney transplantation. This study aimed to compare the quality, the scope, and the consistency of international guidelines on wait-listing for kidney transplantation.

METHODS

Electronic databases and guideline registries were searched to December 2011. The Appraisal of Guidelines for Research and Evaluation II instrument and textual synthesis was used to assess and compare recommendations.

RESULTS

Fifteen guidelines published from 2001 to 2011 were included. Methodological rigor and scope were variable. We identified 4 major criteria across guidelines: recipient age and life expectancy, medical criteria, social and lifestyle circumstances, and psychosocial considerations. Whereas some recommendations were consistent, there were differences in age cutoffs, estimated life expectancy (2-5 years), and glomerular filtration rate at listing (15-20 mL/min/1.73 m). Cardiovascular contraindications were broadly defined. Recommended cancer-free periods also varied substantially, and whereas uncontrolled infections were universally contraindicated, human immunodeficiency virus thresholds and adherence to highly active antiretroviral therapy were inconsistent. Most guidelines recommended psychological screening but were not augmented with specific clinical assessment tools.

CONCLUSIONS

Wait-listing recommendations in current guidelines are based on life expectancy, comorbidities, lifestyle, and psychosocial factors. Some recommendations are different across guidelines or broadly defined. There is a case for developing comprehensive, methodologically robust, and regularly updated guidelines on wait-listing for kidney transplantation.

Chronic kidney disease: highlights for the general pediatrician

Chronic kidney disease in the pediatric population has been increasing. Early detection and treatment can slow down the progression of kidney disease and help prevent the development of end stage renal disease. In addition, as the kidney function declines, there are many pathophysiologic interactions with other organ systems that need to be monitored and treated. In particular, because of impaired vitamin D metabolism, calcium and phosphorus homeostasis is dysregulated and results in secondary bone disease. Anemia is common due to a number of factors including impaired erythropoietin production. Growth is often impacted by chronic kidney disease but can be improved by proper treatment. Complications of chronic kidney disease can be minimized by proper monitoring and treatment of these parameters. The general pediatrician plays a critical role in this process.

Impact of predialysis therapeutic practices on patient outcomes during the first year of dialysis: the Pharmacoepidemiologic AVENIR study

BACKGROUND

Studies evaluating patient outcomes in dialysis as a function of quality of predialysis therapeutic care are lacking.

OBJECTIVE

To evaluate the association of quality of predialysis therapeutic practices with survival and hospitalization during the first year of dialysis.

RESEARCH DESIGN

The AVantagE de la Néphroprotection dans l'Insuffisance Rénale study was an observational cohort study. Cox models explored the association between quality of therapeutic practices and survival over the first year whereas logistic regression measured the association with total duration of hospitalization (0 to 6 d, ≥7 d) among surviving patients at 1 year.

SUBJECTS

All adult patients with chronic kidney disease starting dialysis in Lorraine (France) between 2005 and 2006.

MEASURES

The appropriateness of therapeutic practices was evaluated with reference to current guidelines covering 5 aspects of chronic kidney disease: hypertension/proteinuria, anemia, bone disease, metabolic acidosis, and dyslipidemia. Each patient was then assigned a quality of therapeutic practices rating (high, moderate, or poor) depending on the number of aspects appropriately managed.

RESULTS

Quality of predialysis therapeutic practices was high in 18.2% of the 566 included patients, moderate in 62.5%, and poor in 19.3%. In multivariate analysis, the higher the quality of practices, the better the survival rate during the first year of dialysis [High: hazard ratio (HR) 1; moderate: HR 1.56, P=0.09; poor: HR 1.95, P=0.02]. Conversely, quality of therapeutic practices was not associated with duration of hospitalization among the 390 surviving patients at 1 year.

CONCLUSION

This study suggests that quality of predialysis therapeutic practices is positively associated with survival during the first year of dialysis.

HIV-associated kidney glomerular diseases: changes with time and HAART

BACKGROUND

Treatment and co-morbidities of human immunodeficiency virus (HIV)-infected individuals have changed dramatically in the last 20 years with a potential impact on renal complications. Our objective was to assess the change in distribution of the glomerular diseases in HIV patients.

METHODS

We retrospectively analysed demographic, clinical, laboratory and renal histopathological data of 88 HIV-infected patients presenting with a biopsy-proven glomerular disease between 1995 and 2007.

RESULTS

In our study including 66% Black patients, HIV-associated nephropathy (HIVAN) was observed in 26 cases, classic focal segmental glomerulosclerosis (FSGS) in 23 cases, immune complex glomerulonephritis in 20 cases and other glomerulopathies in 19 patients. HIVAN decreased over time, while FSGS emerged as the most common cause of glomerular diseases (46.9%) in HIV-infected individuals undergoing kidney biopsy in the last 2004-07 period. Patients with HIVAN were usually Black (97%), with CD4 <200/mL (P = 0.01) and glomerular filtration rate <30 mL/min/1.73 m(2) (P < 0.01). Compared to HIVAN, patients with classic FSGS were less often Black (P < 0.01), have been infected for longer (P = 0.03), were more often co-infected with hepatitis C virus (P = 0.05), showed more often cardiovascular (CV) risk factors (P < 0.01), had less often CD4 <200/mL (P = 0.01), lower HIV viral load (P = 0.01) and tended to be older (P = 0.06).

CONCLUSIONS

Classic FSGS associated with metabolic and CV risk factors has overcome HIVAN in HIV-infected patients. Compared with other glomerulopathies, HIVAN remains strongly associated with severe renal failure, Black origin and CD4 lower than 200/mL at presentation.

Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

Considerable variation in grading systems used to rate the strength of guideline recommendations and the quality of the supporting evidence in Nephrology highlights the need for a uniform, internationally accepted, rigorous system. In 2004, Kidney Disease: Improving Global Outcomes (KDIGO) commissioned a methods expert group to recommend an approach for grading in future nephrology guidelines. This position statement by KDIGO recommends adopting the Grades of Recommendation Assessment, Development, and Evaluation (GRADE) approach for the grading of evidence and guidelines on interventions. The GRADE approach appraises systematic reviews of the benefits and harms of an intervention to determine its net health benefit. The system considers the design, quality, and quantity of studies as well as the consistency and directness of findings when grading the quality of evidence. The strength of the recommendation builds on the quality of the evidence and additional considerations including costs. Adaptations of the GRADE approach are presented to address some issues pertinent to the field of nephrology, including (1) the need to extrapolate from studies performed predominantly in patients without kidney disease, and (2) the need to use qualitative summaries of effects when it is not feasible to quantitatively summarize them. Further refinement of the system will be required for grading of evidence on questions other than those related to intervention effects, such as diagnostic accuracy and prognosis.